• Home
  • About us
  • Work & Study
    • Visit us
    • PhD Pathways
    • PhD Project Opportunities
  • Resources and Services
    • Guidelines
    • Clinical Trials
    • Antimicrobial Stewardship
    • Febrile Neutropenia
    • Sepsis Pathway
    • Antibiotic Allergy De- Labelling
    • KIDS dashboard
    • Resources for patients
    • Recent Publications
  • Research
    • Current projects
    • Seminars
  • Newsletter
  • Contact Us
  • Menu

National Centre for Infections in Cancer

  • Home
  • About us
  • Work & Study
    • Visit us
    • PhD Pathways
    • PhD Project Opportunities
  • Resources and Services
    • Guidelines
    • Clinical Trials
    • Antimicrobial Stewardship
    • Febrile Neutropenia
    • Sepsis Pathway
    • Antibiotic Allergy De- Labelling
    • KIDS dashboard
    • Resources for patients
    • Recent Publications
  • Research
    • Current projects
    • Seminars
  • Newsletter
  • Contact Us
blood 2017 car t.png

CAR T cells and infection risk

November 28, 2017

Next gen immunotherapies, such as CAR T cells, have well and truly revolutionised cancer treatment and cure. However, in modifying the immune system (in this case- lymphodepletion with CD19- targeted CAR T cell therapy) there is a potential for altering risk of infection. In this months edition of Blood, Hill et al, retrospectively reviewed the incidence of infections following CD19 CAR T cell therapy in n=133 patients. Key findings include: a risk of infection similar to conventional chemotherapy and that modification of the treatment regimen, specifically- to reduce Cytokine Release Syndrome severity, decreased the frequency of infections. 

With the explosion of next gen immunotherapies in cancer treatment we are excited to see more studies of this nature.

Prev / Next

Search news